Bacil Pharma Limited has received a substantial disposal disclosure from promoter Suman P. Shah under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, dated December 26, 2025. The disclosure pertains to the sale of equity shares by the promoter through market transactions.

Transaction Details

The disposal involved the sale of 500 equity shares by Suman P. Shah, who is classified as a promoter of the company. The transaction was executed through market sale on December 24, 2025.

Shareholding Pattern Changes

The disclosure reveals the complete disposal of Suman P. Shah's shareholding in Bacil Pharma Limited. Prior to this transaction, he held 500 equity shares, representing 0.00% of the total share capital. Following the sale, his shareholding has been reduced to zero.

Company Share Capital Structure

Bacil Pharma Limited's equity share capital structure remains unchanged following this transaction. The company maintains its total equity base with shares listed on the Bombay Stock Exchange.

The disclosure indicates that no encumbrances, voting rights other than equity shares, or convertible securities were involved in this transaction. The seller had no persons acting in concert (PAC) associated with this disposal. This regulatory filing ensures transparency in promoter shareholding changes and compliance with SEBI disclosure requirements for substantial acquisitions and disposals.

Bacil Pharma Limited has announced the proposed appointment of a new Company Secretary following the recent resignation of its previous officer. The company disclosed that Mr. Dikshant Singh Panwar has been proposed for the position of Company Secretary, with confirmation expected in the next board meeting.

Recent Personnel Changes

The appointment comes after Bhavana Phoolchand Tak, who served as the Company Secretary and Compliance Officer, tendered her resignation effective December 1, 2025, to pursue an alternate career opportunity outside the organization.

New Appointment Details

According to the company's communication to BSE Limited dated December 19, 2025, Mr. Dikshant Singh Panwar, a Company Secretary with membership number ACS42741, has been proposed for the role. The company stated that he has extensive experience in compliance services and meets all criteria regarding independence, eligibility, and qualifications as per the Companies Act, 2013, and SEBI regulations.

Regulatory Compliance

Both the resignation and proposed appointment have been disclosed in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has assured stakeholders that the appointment process follows all regulatory requirements.

Financial Context

This leadership transition occurs as Bacil Pharma Limited maintains its operational focus. The company's recent financial position as of March 2025 shows significant growth across key metrics:

The substantial year-over-year increases across these financial metrics highlight the importance of maintaining strong corporate governance and compliance practices during the company's growth phase. The prompt identification and proposed appointment of a qualified replacement demonstrates the company's commitment to maintaining regulatory compliance standards.